Study Sheds New Light on RAS Inhibitors' Role for Advanced CKD Study Sheds New Light on RAS Inhibitors' Role for Advanced CKD
Maintaining treatment with a renin-angiotensin system inhibitor in people with advanced, progressive chronic kidney disease caused no problems compared with stopping it in a randomized study.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 5, 2022 Category: Consumer Health News Tags: Nephrology News Source Type: news
Moving the Needle: SGLT2 Inhibitor Role for Kidney Disease Moving the Needle: SGLT2 Inhibitor Role for Kidney Disease
Empagliflozin significantly cut progression of chronic kidney disease in a pivotal trial that included people without diabetes or heart failure.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - November 4, 2022 Category: Internal Medicine Tags: Nephrology News Source Type: news
Empagliflozin Protects At-Risk Patients From CKD Progression
(MedPage Today) -- Empagliflozin (Jardiance) reduced the risks of chronic kidney disease (CKD) progression and cardiovascular-related deaths in high-risk patients compared with placebo, the phase III EMPA-KIDNEY trial showed.
Over a median 2-year... (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - November 4, 2022 Category: Urology & Nephrology Source Type: news
SGLT2 Inhibitor Role for Isolated Kidney Disease SGLT2 Inhibitor Role for Isolated Kidney Disease
Empagliflozin significantly cut progression of chronic kidney disease in a pivotal trial that included people without diabetes or heart failure.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 4, 2022 Category: Consumer Health News Tags: Nephrology News Source Type: news
EMPA-Kidney Moves the Needle for SGLT2 Inhibitors in Kidney Disease EMPA-Kidney Moves the Needle for SGLT2 Inhibitors in Kidney Disease
Empagliflozin significantly cut progression of chronic kidney disease in a pivotal trial that included people without diabetes or heart failure.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 4, 2022 Category: Cardiology Tags: Nephrology News Source Type: news
Dapagliflozin May Be Cost-Effective for Treating CKD
FRIDAY, Nov. 4, 2022 -- Dapagliflozin seems to be cost-effective in the United Kingdom, Germany, and Spain for patients meeting the eligibility criteria for the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD)... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 4, 2022 Category: Pharmaceuticals Source Type: news
Stop RAS Inhibitors in Advanced CKD? STOP ACEi Trial Sheds Some Light
(MedPage Today) -- Ditching renin-angiotensin system (RAS) inhibitors in advanced chronic kidney disease (CKD) didn't help to slow kidney decline, according to the STOP ACEi trial.
Among patients with a baseline eGFR below 30 mL/min/1.73 m2, eGFR... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 3, 2022 Category: Cardiology Source Type: news
New screening model may optimize early kidney disease detection in Type 1 diabetes
A personalized approach to kidney screening for people with Type 1 diabetes may reduce the time that chronic kidney disease -- for which they are at high risk -- goes undetected, the National Institutes of Health said. (Source: Health News - UPI.com)
Source: Health News - UPI.com - November 2, 2022 Category: Consumer Health News Source Type: news
Trajectories of CKD Symptoms May Predict Later Health Outcomes
MONDAY, Oct. 31, 2022 -- Distinct trajectories of chronic kidney disease (CKD) may predict subsequent health outcomes, according to a study published online Oct. 28 in the Clinical Journal of the American Society of Nephrology.
Moustapha Faye, M.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 31, 2022 Category: Pharmaceuticals Source Type: news
Daprodustat Gets FDA AdComm Nod for Adults With CKD on Dialysis Daprodustat Gets FDA AdComm Nod for Adults With CKD on Dialysis
For the first time, a HIF-PHI-class agent won backing from an FDA advisory committee for treating anemia, but the panel voted against daprodustat for adults with chronic kidney disease not on dialysis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 27, 2022 Category: Consumer Health News Tags: Nephrology News Source Type: news
FDA Panel Gives Thumbs Up to Anemia Pill for CKD Patients on Dialysis
(MedPage Today) -- A group of FDA advisors recommended approval of daprodustat for treating chronic kidney disease (CKD)-related anemia, but only for the subset of patients on dialysis, determining that the same risk-benefit profile did not exist... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 27, 2022 Category: American Health Source Type: news
Prevalence of NAFLD in Patients With Chronic Kidney Disease Prevalence of NAFLD in Patients With Chronic Kidney Disease
This study used CT to assess liver fat content in this group.Nephrology Dialysis Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 27, 2022 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news
Regular Aerobic Exercise May Improve Chronic Kidney Disease Outcomes
TUESDAY, Oct. 25, 2022 -- Regular aerobic exercise is associated with significant improvements in chronic kidney disease (CKD) measures, according to a systematic review and meta-analysis published online Sept. 26 in Frontiers in Physiology.
Qirui... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 25, 2022 Category: Pharmaceuticals Source Type: news
Another CKD-Related Anemia Drug Goes Under the Microscope of FDA Advisors
(MedPage Today) -- An FDA advisory panel will weigh in on whether the safety signals of daprodustat in chronic kidney disease (CKD)-related anemia are too risky to recommend the oral agent for approval.
On Wednesday, the FDA's Cardiovascular and... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 25, 2022 Category: American Health Source Type: news
Ghana: Don't Joke With Your Kidney ... A Survivor Advises
[Ghanaian Times] A survivor of Chronic Kidney Disease (CKD), Abigail Ashley, has implored Ghanaians to be circumspect of their lifestyles and eating habits to safeguard their kidneys. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - October 24, 2022 Category: African Health Source Type: news
